Stock Yards Bank & Trust Co. Sells 8,900 Shares of Stryker Corporation $SYK

Stock Yards Bank & Trust Co. reduced its holdings in shares of Stryker Corporation (NYSE:SYK) by 18.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 40,286 shares of the medical technology company’s stock after selling 8,900 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Stryker were worth $13,238,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after purchasing an additional 133,892 shares during the period. State Street Corp grew its stake in shares of Stryker by 2.1% in the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after purchasing an additional 311,507 shares during the period. Geode Capital Management LLC grew its stake in shares of Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares during the period. Wellington Management Group LLP raised its holdings in shares of Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after buying an additional 1,198,665 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in shares of Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.5%

Shares of SYK opened at $313.38 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a market cap of $120.14 billion, a price-to-earnings ratio of 36.27, a PEG ratio of 2.02 and a beta of 0.78. The stock has a fifty day moving average price of $309.89 and a two-hundred day moving average price of $339.15. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the previous year, the company posted $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Insiders Place Their Bets

In other news, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the transaction, the vice president directly owned 177 shares in the company, valued at approximately $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 in the last 90 days. 4.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of analyst reports. BTIG Research lowered their price target on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Barclays cut their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Robert W. Baird set a $385.00 target price on shares of Stryker in a report on Friday, May 1st. Wells Fargo & Company dropped their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 price target on shares of Stryker in a report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.